Effects of cloricromene on ischemia-reperfusion myocardial damage in the rabbit.

In vitro and in vivo Characterization of the Anti-Inflammatory Effects of Cyclosporin A.

Characterization of the anti-inflammatory effect of FK-506 on human mast cells.

Antiinflammatory effect of FK 506 on human basophils.

The behaviour of protein C in diabetes is still an open question.

[Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].

Heterogeneity of human mast cells and basophils in response to muscle relaxants.

Pharmacological studies in animals of beta-hydroxyethyltheophylline, the major metabolite of doxofylline in humans.

FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells.

Doxofylline differs from methylxanthines in its movement of cytosolic calcium.

Ciclosporin A inhibits mediator release from human Fc epsilon RI+ cells by interacting with cyclophilin.

Falsely increased" B beta 15-42 levels in diabetes.

Serological and molecular studies of HLA in insulin-dependent diabetes mellitus in Sardinia.

Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.

Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?